Charles Milrod, MD

It’s a great joy to share (and teach) what’s exciting about hematology! Here are my go-to threads 🧵 for blood cancer fundamentals 👇

Closing remarks from hem/onc fellowship graduation! Thank you, @BrownMedicine, for the teaching, mentorship, and time. … annnd that’s a wrap on medical oncology fellowship! Next up: let’s go cure cancer 💪🧬

Indolent lymphomas are generally incurable- so are trials reflecting if we live longer *and* feel better? 🤔 We found QoL was: - Collected in 51% of trials - Reported in 24% ‼️ Framed positively even when not improved (!!!) Read more @TheLancetHaem 👇 authors.elsevier.com/a/1ksA98MsWYNW…

So fun to share where I think lymphoma research is headed—and how we might rethink bispecific antibody dosing to work better for patients. Big thanks to @OncoDaily for the feature!

Thanks for sticking around! You can find the full article here: nature.com/articles/s4140…

When does *intention* start in intention-to-treat (ITT) for CART? 🤔 🔑 Current ITT starts at collection 🔑 Problem: Rural/underserved ppl may face delays or fail to reach infusion 💡 Fix? Start ITT at referral! to better capture access disparities More @BloodCancerJnl 👇

Thankful to @ConquerCancerFd and @lymphomatic for the support 🙏 Thanks to all who stopped by in person at #ASH2024! You can read more about this project here 👇 ash.confex.com/ash/2024/webpr…

What happens to T-cells during weekly BiAb treatment? 🤔 ✨ We know T-cell exhaustion drives resistance/relapse in lymphoma ⚠️ But timing is unclear, limiting dosing strategies 💡 We found markers of activation peak early, inhibition later This could guide future dosing trials!

@vit_prochazka @DrRaulCordoba Thank you @vit_prochazka , great to meet you!

OK, lymphoma community, this is really HOT poster by @CharlesMilrod! How CD8 cells are responding to mosu! Definitely schould have been oral. Do not miss it! 👍

What predicts severe bleeding in ITP? 🤔 ✨ What we know: ITP bleeding events occur at lower platelet counts than other causes of thrombocytopenia ⚠️ The problem: Platelet thresholds predicting bleeding in ITP are poorly defined 💡 Our findings: Severe bleeding events were tied to lower platelet counts- but MPV not linked to severity Congrats to mentee @SovijjaPou for turning a great clinical question into impactful research! 👏

@HersheyDudipala @BMCimRES @UCSDCancer Go Hershey!

Graduated from internal medicine residency at Boston University Medical Center! It’s been an amazing 3 years, and I couldn’t have asked for a better place to complete my training. Thank you @BMCimRES for helping me get one step closer to my dreams. @UCSDCancer here I come :)

@Empoweringpts9 @ASCO Thank you, Alison!

@CharlesMilrod @ASCO 👏🏼👏🏼This is awesome!! Congratulations @CharlesMilrod!!

Still buzzing from a great weekend @ASCO! Especially thankful for the Young Investigator Award 👇 Our work in T-cell exhaustion 🥱💤 will help us design *evidence-based* treatment regimens for indolent lymphomas. Cheers to the future! 🎉

@RohangantiMD @ASCO Thank you, Rohan!

@CharlesMilrod @ASCO Congratulations brother! Goals

@JamesMartinCLE Thank you!

@CharlesMilrod Congratulations! 🍾

So stoked to receive @ASCO’s Young Investigator Award! Honored to be among this incredible group 🤯 Thank you to my mentor @lymphomatic and the support from @BrownUniversity More to come!

@OncSadr @ASCO @lymphomatic @BrownUniversity Thank you, Hossein!!

@CharlesMilrod @ASCO @lymphomatic @BrownUniversity Congrats!

Excited to share our latest on Hodgkin lymphoma! When I was preparing this topic for grand rounds👇 I couldn’t find a review on what I needed… … so I made it myself! Check it out here: frontiersin.org/journals/oncol…

@QuinlanSievers @MatthewHoMD @BrJHaem Great question! Age definitely plays a role. This paper found that for those <60 y/o, progressive FL accounts for ~50% of deaths and for >70 y/o, ~33% of deaths 👇 Regardless of age, these are big numbers!

@CharlesMilrod @MatthewHoMD @BrJHaem Congrats on the paper! Q - Could the weak correlation between PFS and OS be explained by the fact that many patients are older and may pass away due to a cause unrelated to the FL? If you run the analysis only on patients younger than say, 50, does the correlation change?

In follicular lymphoma, is PFS a strong surrogate for OS? 🔊 NO! 🔑 PFS is the most commonly used surrogate for drug registration in FL 👎 PFS is *weakly* associated with OS 🤯 Only 15% of variance in OS is explained by PFS Read more in @BrJHaem 👇 onlinelibrary.wiley.com/share/author/F…

@VPrasadMDMPH @FDAOncology Thank you, Vinay!

Charles knows how to run surrogate validation studies. This week @FDAOncology is going to try to ram MRD as an accelerated approval endpoint for myeloma. There is no way they have RoBUST trial level data. They're going to rely on low-level prognostic data at best.